UK warns of major cholera outbreak in Mariupol, Ukraine

European News

The UK’s Ministry of Defence has said that Mariupol, now controlled by Russian forces after weeks of siege and heavy bombardment, is at risk of a major cholera outbreak. “There is likely a critical shortage of medicines in Kherson, while Mariupol is at risk of a major cholera outbreak. Isolated cases of cholera have been reported since May,” the UK Defence Ministry said in the latest intelligence update.

The city’s exiled deputy mayor says the 100,000 people still in the city are at increasing risk of the disease.

Russia is currently struggling to provide basic public services to the population in Russianoccupied territories. Access to safe drinking water has been inconsistent, while major disruption to telephone and internet services continues. Ukraine suffered a major cholera epidemic in 1995, and has experienced minor outbreaks since. Medical services in Mariupol are likely already near collapse: a major cholera outbreak in Mariupol will exacerbate this further.

Expressing concern over the situation, Mariupol Mayor, Vadym Boychenko, said, “Without medicine and medical care, the restoration of water supply and proper sewerage in the city will erupt epidemics.”

UK defence chiefs have also said that there is likely to be a critical shortage of medicines in Kherson, another city in southern Ukraine.

Cholera is a very serious illness, which can kill within hours if left untreated. The spread of cholera is closely linked to poor sanitation facilities and unsafe drinking water, where the disease can thrive and spread. Vaccines, combined with improvements in water and sanitation, can help get cholera outbreaks under control.

European Commission delays release of major changes to pharma legislation

The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The decision was previously expected on 29 March 2023, but has been announced to be “slightly later”.

AstraZeneca’s NMOSD treatment recommended marketing

Pharma giant AstraZeneca has been given a recommendation by the EU's Committee for Medicinal Products (CHMP) for marketing authorisation for ultomiris (ravulizumab), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMSOD) who are anti-aquaporin-4 (AQP4) antibody positive (ab+).

AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease

AbbVie has announced that it has received positive feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of upadacitinib (rinvoq) for the treatment of adult patients with moderate to severe crohn’s disease who have had an inadequate response, lost response or were intolerant to conventional therapies or biologic agents.

CSL receives CMA from the European Commission for haemophilia B drug

CSL, a biotech company, has announced that it has received conditional marketing authorisation (CMA) from the European Commission (EC) for its haemophilia b drug hemgenix.

Merck to appeal EU rejection of COVID-19 drug

Life sciences giant Merck & Co has announced that it will appeal the EU's committee for Medicinal Products for Human Use’s (CHMP) decision to not recommend approval for its COVID-19 drug lagevrio.

European Commission delays release of major changes to pharma legislation

AstraZeneca’s NMOSD treatment recommended marketing

AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease

CSL receives CMA from the European Commission for haemophilia B drug

Merck to appeal EU rejection of COVID-19 drug

Pharmafocus

Categories

Social Footprints